AbbVie

Yahoo Finance • 3 days ago

This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity therapies -- are now well known and are gene... Full story

Yahoo Finance • 9 days ago

SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.1 MONTREAL, March 4, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab... Full story

Yahoo Finance • 9 days ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

NORTH CHICAGO, Ill., March 4, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Management will participate in a fireside chat at 7:40 a.m. Central ti... Full story

Yahoo Finance • 27 days ago

John Rogers' Strategic Moves: A Closer Look at Royal Caribbean Group's Impact

Exploring the Latest 13F Filing and Key Investment Adjustments John Rogers (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2024, providing insights into his investment moves during this period. John Rogers... Full story

Yahoo Finance • 28 days ago

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable May 15, 2025, to stockholders of record at the... Full story

Yahoo Finance • 29 days ago

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 a... Full story

Yahoo Finance • last month

3 Fabulous Dividend Stocks to Buy in February

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month. Here's why they like... Full story

Yahoo Finance • last month

68-Year-Old Earning $4,300/Month in Dividends Shares His Top 7 Stock Picks — 'Dividends Have Been Consistent, Stable'

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. U.S. markets were seeing volatility as technology earnings began to worry investors due to soft forecasts and mounting AI-related expense... Full story

Yahoo Finance • last month

3 US Stocks Estimated To Be Undervalued For Savvy Investors

As the U.S. market hovers near record highs, investors are closely monitoring the upcoming January jobs report for insights into economic health and interest rate trends. In this environment, identifying stocks that may be undervalued can... Full story

Yahoo Finance • last month

3 Stocks That Investors Might Be Undervaluing By Up To 43.3%

In the current global market landscape, investors are navigating a complex environment marked by fluctuating interest rates, geopolitical tensions, and volatile corporate earnings. With U.S. stocks experiencing a mixed performance and Euro... Full story

Yahoo Finance • last month

If You Invested $10,000 In AbbVie Stock 10 Years Ago, How Much Would You Have Now?

If You Invested $10,000 In AbbVie Stock 10 Years Ago, How Much Would You Have Now? Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AbbVie Inc. (NYSE:ABBV) discovers, develops, manufact... Full story

Yahoo Finance • 2 months ago

Is AbbVie Inc. (ABBV) The Best Bear Market Stock To Invest In Now?

We recently published a list of 11 Best Bear Market Stocks To Invest In Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best bear market stocks to invest in now. As of January 2025,... Full story

Yahoo Finance • 2 months ago

Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever

You've probably heard this before: Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs doctors and patients rely on -- and that means no matter what the economy is doing,... Full story

Yahoo Finance • 2 months ago

Top Wall Street Analyst Says Dump The Magnificent 7 And Go All In On These Three Big Pharma Dividend Stocks

Top Wall Street Analyst Says Dump The Magnificent 7 And Go All In On These Three Big Pharma Dividend Stocks Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. 2024 was a great year for in... Full story

Yahoo Finance • 5 months ago

BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)

The Only Product of Its Kind Approved for Use in Four Aesthetic Indications: Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines, Frown Lines, Crow's Feet Lines, and Now Platysma Bands in Adults1-5 With this Approv... Full story

Yahoo Finance • 5 months ago

U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease

VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV reported superior improvement in "on" time... Full story

Yahoo Finance • 5 months ago

Dividend Investor Who 'Doubled' His Passive Income to $1,000 a Month in Six Months Reveals Portfolio: Top 8 High-Yield Stocks

Dividend Investor Who 'Doubled' His Passive Income to $1,000 a Month in Six Months Reveals Portfolio: Top 8 High-Yield Stocks Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. As enthusi... Full story

Yahoo Finance • 5 months ago

Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade

The major U.S. stock market indexes are officially in overheated territory thanks to enthusiasm for artificial intelligence (AI). Since the end of 2022, the most popular benchmark, the S&P 500 index, has soared about 51% to a rich valuatio... Full story

Yahoo Finance • 5 months ago

Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal

Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (... Full story

Yahoo Finance • 5 months ago

AbbVie Inc. (ABBV) Projects Mid-Single-Digit Sales Growth Over Next 3 Years

We recently published a list of 8 Best Inexpensive Stocks To Invest In Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other best inexpensive stocks to invest in now. Are Experts Alrea... Full story